# Husseini K. Manji

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/husseini-k-manji/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,161 |
| Field | Treatment of Major Depression |
| h-index | 101 |
| i10-index | 210 |
| Last Known Institution | Yale University |
| OpenAlex ID | https://openalex.org/A5103004624 |
| ORCID iD | https://orcid.org/0000-0003-0181-8173 |
| Works | 873 |

## Researcher papers

Showing 12 of 14.

- [A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression](https://scholariq.org/papers/a-randomized-trial-of-an-n-methyl-d-aspartate-antagonist-in-treatment-resistant/)
- [The cellular neurobiology of depression](https://scholariq.org/papers/the-cellular-neurobiology-of-depression/)
- [Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-flexibly-dosed-esketamine-nasal-spray-combined-with-a/)
- [Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/efficacy-of-esketamine-nasal-spray-plus-oral-antidepressant-treatment-for/)
- [Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression](https://scholariq.org/papers/efficacy-and-safety-of-intranasal-esketamine-adjunctive-to-oral-antidepressant/)
- [Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-intranasal-esketamine-for-the-rapid-reduction-of-symptoms/)
- [Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)](https://scholariq.org/papers/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new/)
- [A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression](https://scholariq.org/papers/a-double-blind-randomized-placebo-controlled-dose-frequency-study-of-intravenous/)
- [Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3](https://scholariq.org/papers/efficacy-and-safety-of-esketamine-nasal-spray-plus-an-oral-antidepressant-in/)
- [Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study](https://scholariq.org/papers/intravenous-esketamine-in-adult-treatment-resistant-depression-a-double-blind/)
- [Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)](https://scholariq.org/papers/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients/)
- [A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression](https://scholariq.org/papers/a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major/)

## Researcher topics

- [Treatment of Major Depression](https://scholariq.org/topics/treatment-of-major-depression-2/)
- [Bipolar Disorder and Treatment](https://scholariq.org/topics/bipolar-disorder-and-treatment/)
- [Tryptophan and brain disorders](https://scholariq.org/topics/tryptophan-and-brain-disorders-2/)
- [Neuroscience and Neuropharmacology Research](https://scholariq.org/topics/neuroscience-and-neuropharmacology-research/)
- [Neurotransmitter Receptor Influence on Behavior](https://scholariq.org/topics/neurotransmitter-receptor-influence-on-behavior/)

## Researcher university

- [Yale University](https://scholariq.org/institutions/yale-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.